Disc Medicine Inc
IRON58.940USD
-0.030-0.05%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.04BCap. mercado
PérdidaP/E TTM
Más Datos de Disc Medicine Inc Compañía
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
Información de la empresa
Símbolo de cotizaciónIRON
Nombre de la empresaDisc Medicine Inc
Fecha de salida a bolsaAug 12, 2020
Director ejecutivoDr. John D. Quisel, J.D., Ph.D.
Número de empleados84
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 12
Dirección321 Arsenal Street, Suite 101
CiudadWATERTOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02472
Teléfono16176749274
Sitio Webhttps://www.discmedicine.com/
Símbolo de cotizaciónIRON
Fecha de salida a bolsaAug 12, 2020
Director ejecutivoDr. John D. Quisel, J.D., Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Ms. Mona Ashiya, Ph.D.
Ms. Mona Ashiya, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Access Industries, Inc.
10.27%
Fidelity Management & Research Company LLC
8.81%
Atlas Venture
6.88%
Wellington Management Company, LLP
6.77%
Frazier Life Sciences Management, L.P.
5.07%
Other
62.20%
Accionistas
Accionistas
Proporción
Access Industries, Inc.
10.27%
Fidelity Management & Research Company LLC
8.81%
Atlas Venture
6.88%
Wellington Management Company, LLP
6.77%
Frazier Life Sciences Management, L.P.
5.07%
Other
62.20%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
36.42%
Investment Advisor/Hedge Fund
20.13%
Hedge Fund
15.45%
Venture Capital
12.60%
Private Equity
10.69%
Corporation
10.27%
Research Firm
1.08%
Individual Investor
0.44%
Bank and Trust
0.33%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
343
37.31M
107.73%
+1.83M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
2023Q2
190
22.86M
100.53%
+3.93M
2023Q1
169
18.38M
96.84%
-1.35M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Access Industries, Inc.
3.56M
10.27%
--
--
Feb 27, 2025
Fidelity Management & Research Company LLC
3.05M
8.81%
+1.32M
+76.31%
Mar 31, 2025
Atlas Venture
2.38M
6.88%
-125.00K
-4.98%
Mar 31, 2025
Wellington Management Company, LLP
2.34M
6.77%
+948.09K
+67.94%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.75M
5.07%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.75M
5.06%
+219.74K
+14.35%
Mar 31, 2025
RA Capital Management, LP
1.58M
4.55%
+1.58M
--
Mar 31, 2025
Janus Henderson Investors
1.42M
4.11%
+205.44K
+16.87%
Mar 31, 2025
OrbiMed Advisors, LLC
1.42M
4.09%
-370.55K
-20.75%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.34M
3.87%
-36.42K
-2.65%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ALPS Medical Breakthroughs ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
SPDR S&P Biotech ETF
0.42%
Direxion Daily S&P Biotech Bull 3X Shares
0.24%
ProShares Ultra Nasdaq Biotechnology
0.2%
Invesco Nasdaq Biotechnology ETF
0.2%
iShares Health Innovation Active ETF
0.14%
iShares Biotechnology ETF
0.12%
JPMorgan Fundamental Data Science Small Core ETF
0.12%
Fidelity Fundamental Small-Mid Cap ETF
0.11%
Ver más
ALPS Medical Breakthroughs ETF
Proporción1.24%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.9%
SPDR S&P Biotech ETF
Proporción0.42%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.24%
ProShares Ultra Nasdaq Biotechnology
Proporción0.2%
Invesco Nasdaq Biotechnology ETF
Proporción0.2%
iShares Health Innovation Active ETF
Proporción0.14%
iShares Biotechnology ETF
Proporción0.12%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.12%
Fidelity Fundamental Small-Mid Cap ETF
Proporción0.11%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Dec 29, 2022
Merger
10<1
Dec 29, 2022
Merger
10<1
Dec 29, 2022
Merger
10<1
Dec 29, 2022
Merger
10<1
Fecha
Tipo
Relación
Dec 29, 2022
Merger
10<1
Dec 29, 2022
Merger
10<1
Dec 29, 2022
Merger
10<1
Dec 29, 2022
Merger
10<1
